Jefferies upgrades Zydus Life to ‘Buy’ on strong US pipeline potential, stock up 4%

August 28, 2024

Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.

More To Explore

FPIs record unprecedented Rs 1.13 lakh crore sell-off in October, remain buyers in cash market

The duality in the behavior of FPIs is explained by Dr. V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services, stating that the primary

November 2, 2024

Amitabh Bachchan to Rahul Dravid: Know the star-studded lineup of Swiggy’s celebrity investors as IPO nears

Swiggy’s anticipated IPO next week has generated significant interest among celebrity investors and institutional firms. With the online food delivery market projected to grow at

November 2, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003